|Articles|September 24, 2015
Lecia V. Sequist on Side Effects From Agents for Resistant Lung Cancer
Author(s)Lecia V. Sequist
Lecia V. Sequist, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291).
Advertisement
Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, discusses the adverse event profiles of rociletinib (CO-1686) and osimertinib (AZD9291), two agents specific to acquired T790M mutations in EGFR-positive non-small cell lung cancer (NSCLC).
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
2
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
3
Wildfire Smoke and Cancer Risk: What Patients Should Know
4
Family History of Cancer Fuels Oncology Nurse's Passion for Patient Care
5